# Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

> **NCT00211354** · PHASE2 · WITHDRAWN · sponsor: **Manhattan Eye, Ear & Throat Hospital**

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **DRUG:** Anecortave Acetate

## Key facts

- **NCT ID:** NCT00211354
- **Lead sponsor:** Manhattan Eye, Ear & Throat Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-03
- **Primary completion:** 2007-03
- **Final completion:** 2007-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects enrolled
- **Last updated:** 2009-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211354, "Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00211354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*